Company intelligence / Profile preview

EpiCept Corporation

Tarrytown, New York, United Statesbiospace.com ↗

Ownership: Private
Development stage: Phase 3

Overview

EpiCept developed Ceplene which received marketing authorization in Europe for AML remission maintenance. The company also had several pain therapies in clinical development before merging with Immune Pharmaceuticals.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small moleculesantibody therapeutics (post-merger)
Industry: Biotech

Drug pipeline

2 assets

Crolibulin

1 more asset in the full pipeline.

Request access →

Partnerships

Adolor Corporation (for LidoPAIN SP in North America)Endo

Beyond the preview

Go deeper on EpiCept Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiCept Corporation.

Explore the full profile